Table 1.

Experimental groups.

Donor	Recipient	Treatment	Group purpose	Assessments (days)
C57BL/6	C57BL/6	Vehicle	Vehicle-treated syngeneic control	4, 8–14, 20, 28
BALB/c	C57BL/6	Vehicle	Vehicle-treated allogeneic control	4, 8–14, 20, 28
BALB/c	C57BL/6	AON-D21	C5a inhibition	4, 8–14, 20, 28
BALB/c	C57BL/6	Anti-CD25 + AON-D21	Regulatory T cell depletion and C5a inhibition	8

Sample size (n) = 4–6 transplants/time point/experiment (repeats of three experiments).